A PHASE 1 STUDY TO EVALUATE THE BIOEQUIVALENCE OF ORAL TABLET AND ORALLY DISSOLVING TABLET FORMULATIONS OF RIMEGEPANT, A SMALL MOLECULE CGRP RECEPTOR ANTAGONIST

被引：0
|
作者：
Croop, R. [1 ]
Ivans, A. [1 ]
Stock, D. [1 ]
Hould, J. [1 ]
Morris, B. A. [1 ]
Stringfellow, J. [1 ]
Jensen, C. M. [1 ]
Moulin, J. -A. [2 ]
Larouche, R. [2 ]
Tanguay, M. [2 ]
Coric, V. [1 ]
Lipton, R. B. [3 ]
机构：
[1] Biohaven Pharmaceut, New Haven, CT USA
[2] Syneos Hlth, Quebec City, PQ, Canada
[3] Albert Einstein Coll Med, New York, NY USA
来源：
CEPHALALGIA | 2018年 / 38卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-1
引用
收藏
页码：142 / 143
页数：2
相关论文
共 50 条
  • [1] A Phase 1 Study to Evaluate the Bioequivalence of Oral Tablet and Orally Dissolving Tablet Formulations of Rimegepant in Healthy Adult Subjects Under Fasting Conditions
    Croop, R.
    Ivans, A.
    Stock, D.
    Hould, J.
    Morris, B. A.
    Stringfellow, J.
    Moulin, J.
    Larouche, R.
    Tanguay, M.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2018, 58 (08): : 1303 - 1304
  • [2] Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults
    Croop, Robert
    Bhardwaj, Rajinder
    Anderson, Matt S.
    Matschke, Kyle T.
    Hould, Jennifer
    Bertz, Richard
    Liu, Jing
    Lipton, Richard B.
    CEPHALALGIA, 2024, 44 (02)
  • [3] A bioequivalence study of two oral desmopressin tablet formulations
    Kaehler, Stefan T.
    Steiner, Ilka M.
    Sauermann, Robert
    Scheidl, Helmut
    Mueller, Markus
    Joukhadar, Christian
    PHARMACOLOGY, 2006, 77 (01) : 46 - 52
  • [4] A bioequivalence study of two oral desmopressin tablet formulations
    Steiner, I
    Sauermann, R
    Kaehler, S
    Lackner, E
    Zeleny, P
    Müller, M
    Joukhadar, C
    PHARMACOLOGY, 2005, 75 (04) : 205 - 205
  • [5] A PHASE 1 OPEN-LABEL CROSSOVER STUDY TO EVALUATE BIOEQUIVALENCE OF ORAL SUSPENSION AND TABLET FORMULATIONS OF PERAMPANEL IN HEALTHY SUBJECTS
    Laurenza, A.
    Hall, N.
    Majid, O.
    Rege, B.
    EPILEPSIA, 2016, 57 : 170 - 171
  • [6] Bioequivalence study of two mirtazapine oral tablet formulations in healthy Chinese male volunteers
    Zheng, Li
    Yu, Qin
    Miao, Jia
    Xiang, Jin
    Xu, Nan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (05) : 368 - 374
  • [7] Bioequivalence study of two oral tablet formulations containing tenofovir disoproxil fumarate in healthy volunteers
    Yerino, Gustavo A.
    Halabe, Emilia K.
    Zini, Elvira
    Feleder, Ethel C.
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2011, 61 (01): : 55 - 60
  • [8] Human Bioequivalence Study of Clarithromycin from Two Tablet Formulations after Single Oral Administration
    Ioannis Niopas
    Athanasios C. Daftsios
    Nicolaos Nikolaidis
    Clinical Drug Investigation, 2001, 21 : 211 - 217
  • [9] Human bioequivalence study of clarithromycin from two tablet formulations after single oral administration
    Niopas, I
    Daftsios, AC
    Nikolaidis, N
    CLINICAL DRUG INVESTIGATION, 2001, 21 (03) : 211 - 217
  • [10] Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
    Lipton, Richard B.
    Thiry, Alexandra
    Morris, Beth A.
    Croop, Robert
    JOURNAL OF PAIN RESEARCH, 2024, 17 : 2431 - 2441
12345